Home/ Stocks/ MNPR

Monopar Therapeutics Inc. Common Stock

MNPR XNAS

$55.25 -1.01 (-1.80%) ▼ 15-min delayed

Open

$55.63

High

$57.04

Low

$53.59

Volume

126.8K

Market Cap

$375.96M

About Monopar Therapeutics Inc. Common Stock

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 16 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$0	$-3,437,601	$-0.48
Q2 2025	$0	$-2,453,526	$-0.35
Q1 2025	$0	$-2,624,972	$-0.38
FY 2024	$0	$-15,586,419	$-4.11

Related Market News

No specific coverage for MNPR yet. Check out our latest market news or earnings calendar.

Get MNPR Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Monopar Therapeutics Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.